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Obstructive nephropathy: Insights from genetically engineered
animals. Congenital obstructive nephropathy is the primary
cause for end-stage renal disease (ESRD) in children. An
increasingly used animal model of obstructive nephropathy
is unilateral ureteral obstruction (UUO). This model mim-
ics, in an accelerated manner, the different stages of obstruc-
tive nephropathy leading to tubulointerstitial fibrosis: cellular
infiltration, tubular proliferation and apoptosis, epithelial-
mesenchymal transition (EMT), (myo)fibroblast accumulation,
increased extracellular matrix (ECM) deposition, and tubular
atrophy. During the last decade genetically modified animals
are increasingly used to study the development of obstructive
nephropathy. Although the use of these animals (mainly knock-
outs) has highlighted some pitfalls of this approach (compen-
sation by closely related gene products, absence of temporal
knockouts) it has brought important information about the
role of specific gene-products in the pathogenesis of obstructive
nephropathy. Besides confirming the important pathologic role
for angiotensin II (Ang II) and transforming growth factor-b
(TGF-b) in obstructive nephropathy, these animals have shown
the complexity of the development of tubulointerstitial fibro-
sis involving a large number of closely functionally related
molecules. More interestingly, the use of these animals has led to
the discovery of unexpected and contradictory roles (both po-
tentially pro- and antifibrotic) for Ang II, for ECM degrading
enzymes matrix metalloproteinase 9 (MMP-9) and tissue plas-
minogen activators (PAs), for plasminogen activator inhibitor
1 (PAI-1), and for the adhesion molecule osteopontin (OPN)
in obstructive nephropathy. Further use of these animals, es-
pecially in combination with pharmacologic tools, should help
to better identify potential antifibrotic strategies in obstructive
nephropathy.
Obstructive nephropathy and obstructive uropathy are
often used names to describe renal disease leading to hy-
dronephrosis caused by obstruction of the urinary tract.
This pathology is common in infants due to congenital
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abnormalities of the urinary tract, most frequently poste-
rior urethral valves and uteropelvic junction obstruction
[1]. In children, obstructive nephropathy is the primary
cause for end-stage renal disease (ESRD) and represents
16.1% of all pediatric transplantations in North America
[2] while obstructive nephropathy is at the origin of 0.3%
ESRD patients in the total North American population
[3]. The incidence of obstructive nephropathy declines
after childhood and re-appears around the age of 60 to
65 years, particularly in men caused by prostate disease
[4]. In the adult kidney, ureteral obstruction leads to in-
terstitial fibrosis and tubular atrophy, while urinary tract
obstruction in the maturing kidneys also permanently im-
pairs renal development [5].
Different animal models were used in attempts to study
the pathophysiology of congenital obstructive uropathy
(see [6] for an extensive review). Briefly, engineered mu-
tation of genes such as Pax-2 [7], and angiotensin type 2
(AT2) receptor deficiency [8] or spontaneously appear-
ing genetic modifications in rat [9] or mouse strains [10]
can lead to hydronephrosis associated to tubular atro-
phy and interstitial fibrosis. Unfortunately, the cause of
the hydronephrosis in these models was found not to be
necessarily due to hydrostatic obstruction. Fetal ureteral
obstruction can also be induced by surgery but experi-
ments have to be performed using big animals such as
sheep or monkeys. A promising study used fetal ureteral
obstruction in the rhesus monkey [11] and analyzed re-
nal function recovery as a function of obstruction time
and/or the severity but also the level of the obstruction.
The major, obvious, drawbacks of the use of big animals
are the handling and housing problems and their price. Fi-
nally, partial ureteral obstruction (i.e., the situation that is
most frequently encountered in humans) can be obtained
by burying the left ureter into the psoas muscle, but this
kind of surgery leads to a poorly reproducible obstruction
making it hard to obtain homogenous animal groups.
Besides these congenital or partial obstruction models,
an increasingly used and popular animal model (mainly
rat and mice) of obstructive nephropathy is complete
unilateral ureteral obstruction (UUO) which can be per-
formed either in newborn [12] or in adult rats and mice.
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Fig. 1. Overview of the different stages of the development of obstructive nephropathy. Rapidly after unilateral ureteral obstruction (UUO)
cytokines and growth factors secreted by tubular epithelial cells induce cell infiltration (mainly macrophages) that in their turn also secrete growth
factors and cytokines inducing a disequilibrium between apoptosis and proliferation of tubular cells, as well as inducing fibroblast activation and
proliferation. Fibroblasts either infiltrate from the circulation into the interstitium, appear by epithelial-mesenchymal transition (EMT) or appear
by proliferation of the few resident fibroblasts. Activated fibroblasts secrete the extracellular matrix (ECM) that is starting to accumulate into the
interstitium as soon as myofibroblasts appear. As the obstruction continuous, ECM deposition becomes massive and uncontrolled apoptosis of
tubular cells results in tubular atrophy. The involvement of different molecules in these stages of obstructive nephropathy, studied using genetically
modified animals, is described in the text and in the subsequent figures.
Performing UUO in newborn rat and mice allows study-
ing the effect of obstruction on renal development since
in mice and rats, in contrast to humans, only 10% of
nephrons are formed at birth with the remainder devel-
oping in the first postnatal week [13]. One can regret the
limited number of studies using the UUO model in engi-
neered animals in the first day of life.
The UUO maneuver leads to acute and complete
obstruction of the ureter which as mentioned above
is rarely found in humans but it has the advantage
that it mimics, in an accelerated manner, the different
stages of obstructive nephropathy leading to tubuloin-
terstitial fibrosis: cellular infiltration, tubular prolifer-
ation and apoptosis, epithelial-mesenchymal transition
(EMT), (myo)fibroblast accumulation, increased extra-
cellular matrix (ECM) deposition, and tubular atrophy
(Fig. 1). These different features of the pathology appear
rapidly, all within around 1 week after the induction of
the pathology and are highly reproducible from one ex-
periment to another.
UUO: THE PREGENETIC ENGINEERING ERA
Before the use of genetically modified mice to study ob-
structive nephropathy, the UUO model, using gene ex-
pression analysis and pharmacologic tools, had already
largely proven its usefulness by identifying a number
of important molecules and processes involved in the
pathogenesis of obstructive nephropathy [14]. For exam-
ple production of angiotensin II (Ang II) was identified,
acting via transcription factor nuclear factor NF-jB (NF-
jB), tumor necrosis factor-a (TNF-a), and transforming
growth factor-b (TGF-b), as an important cause of fi-
brosis. Consequently blockage of the renin-angiotensin
system (RAS) by angiotensin-converting enzyme (ACE)
inhibition is significantly reducing renal fibrosis in this
obstructive nephropathy model [15–17]. However, as dis-
cussed later, recent evidence using genetically engineered
mice has shown that angiotensin type 1 (AT1) receptor
stimulation can also be beneficial in UUO [18]. Similarly,
endogenous inhibition of ECM degrading enzyme activ-
ity was incriminated for a long time as an important cause
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Table 1. Effects of unilateral ureteral obstruction (UUO) on the different stages of development of obstructive nephropathy
Inflammation Proliferation EMT Apoptosis Tubular atrophy Fibrosis References
Cellular infiltration
Osteopontin knockout − + − [29]
CD44 knockout − = = + + − [31]
E, P, L-selectin knockouta − − = (day 5) − (day 14) = (day 5) − (day 14) [32]
L-selectin knockouta − = = (day 5) − (day 14) = (day 5) − (day 14) [32]
Sulfatide knockouta − [35]
CCR1 − − = − [36]
CCR5 = = = = [36]
Proliferation apoptosis
p21CIP1/WAF1 knockout = = + = = [42]
p27KIP1 knockout + + [41]
p53 knockout − − − [48]
Extracellular matrix
Plasminogen knockoutb − = − [98]
tPA knockout − − [21]
PAI-1 knockout − − − [20]
uPAR knockoutc − − + + + [66]
TIMP-1 knockout = [70]
Renin-angiotensin system-related
Angiotensinogen knockouta = − [75]
Angiotensinogen 1 to 4 = + with increasing [75]
gene copiesa copies
AT1 receptor knockout − − [76]
AT2 receptor knockout = = + = + [77]
Double TNF-a receptor knockout − − [81]
Bradykinin B2 receptor knockout − = = + [84]
Kallikrein overexpressing rats − [84]
TGF-b
Smad3 knockout − − −c − [93, 99]c
Integrin avb 6 knockout = − − [94]
Decorin knockout + + + + [95]
Endoglin knockout (+/−) = [96]
Abbreviations are: tPA, tissue plasminogen; PAI-1, plasminogen activator protein-1, uPAR, urokinase plasminogen activator receptor; TIMP, tissue inhibitors of
matrix metalloproteinase; AT1, angiotensin type 1, AT2, angiotensin type 2; TNF-a, tumor necrosis factor-a; TGF-b , transforming growth factor-b ; = , no difference;
−, decrease; +, increase. Observations on day 5 or 7 after UUO compared to wild-type mice.
aResults after 28 of UUO; b21 days after UUO; c14 days after UUO.
for ECM accumulation [19] in UUO but the use of knock-
out mice has changed this vision [20, 21].
UUO: INSIGHTS FROM GENETICALLY
ENGINEERED ANIMALS
In the current review we attempt to describe the
contribution of genetically engineered animals (mainly
gene-knockouts (see Table 1) but also some animals over-
expressing specific proteins) to the current understanding
of the development of interstitial fibrosis in obstructive
nephropathy.
A major drawback in knockout mice is the apparent
redundancy of biologic molecules. Possible compensa-
tion during development and during the induction of the
pathology might false the interpretation of data obtained
using knockout mice. Effects of knockouts that are ob-
served in the initiation phase of the pathology but fade
out when the pathology progresses are quite frequent
and might be explained by adaptation. It is therefore im-
portant to confirm observations, if possible, by pharma-
cologic knockouts. Another important issue is that one
should compare the results of the knockout mice with
adequate control strains (either control mice obtained
by repeated (eight to ten) backcrosses to obtain the ge-
netic background of one of the parent strains or control
mice obtained by parallel breeding of both the control
and the knockout strain on a mixed genetic background)
since the different mouse strains are not likely to produce
identical responses to the pathologic insults. Finally, it is
preferable to examine the kidney structure of genetically
engineered animals before undertaking UUO. Indeed,
some knockout animals, including the angiotensinogen,
AT1 [22], or AT2 [8] receptor knockout mice generate
animals with impaired renal development and histologic
lesions that look like to those obtained after an UUO.
Rather than simply reporting all published data, we
have tried to describe, when possible, the more unusual
or nonexpected results obtained using genetically modi-
fied animals. The paper is divided into the different stages
of the development of obstructive nephropathy (Fig. 1).
Furthermore, there are two additional sections on two
“molecules” currently identified as the main actors in
the fibrotic process: the RAS and TGF-b . For a quick
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Fig. 2. Hypothetic representation of cellular
infiltration in unilateral ureteral obstruction
(UUO) based on data obtained with knock-
out mice. UUO induces macrophage infil-
tration in the tubulointerstitium. In UUO,
the interaction between L-selectin and sul-
fatide seems to mediate the initial contact
(rolling) between macrophages and the vascu-
lar endothelium. These rolling macrophages
are exposed to adhesion molecules like
chemokines and osteopontin expressed on
endothelial cells. The chemokines bind to
chemokine receptors (in UUO mainly the
CCR1) on the macrophages. Osteopontin
binds to the CD44 receptor. This results in
firm adhesion and transendothelial migration
of macrophages. The role of other impor-
tant molecules [including intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell ad-
hesion molecule-1 (VCAM-1), and monocyte
chemoattractant protein-1 (MCP-1)] involved
in cellular infiltration shown to be induced in
UUO has not been studied yet and should give
a more complete picture of cellular infiltration
in UUO.
appreciation of the effect of a specific knockout on a
typical parameter during the development of obstructive
nephropathy, the reader is referred to Table 1.
CELLULAR INFILTRATION
Macrophages are rare in the healthy renal cortex [23].
However, a few hours after ureteral obstruction a large
number of blood-derived macrophages accumulate in
the tubulointerstitial space [4]. This cellular infiltration
(Fig. 2) is preceded by local expression of chemokines [24,
25], chemokine receptors [24], and adhesion molecules
[26, 27]. Despite strong correlative data, no functional
studies describing the role of these molecules in UUO-
induced cellular infiltration have been described. The use
of knockout mice allowed discrimination between simple
fortuitous induction and genuine involvement in cellular
recruitment of some of these molecules in UUO-induced
nephropathy.
Adhesion molecules: Osteopontin and selectins
Osteopontin (OPN) is an adhesion molecule that binds
to macrophages and mediates their adhesion in vitro.
Injection of OPN neutralizing antibody in rats or mice
significantly reduces macrophage infiltration induced by
a chemotactic peptide [28]. Furthermore, OPN is up-
regulated in UUO [25]. UUO using OPN null mu-
tants (OPN−/−) confirmed the important role of OPN in
macrophage recruitment since these mice have around
75% less tubulointerstitial macrophages than their wild-
type littermates [29]. This difference was translated into
significantly less TGF-b and tubulointerstitial collagen
expression. A surprising observation in this study was
the increased number of interstitial and tubular apoptotic
cells in OPN−/− mice. However, no correlation could be
observed between the number of macrophages and the
number of apoptotic cells suggesting that OPN can di-
rectly act as a cell survival factor. This newly discovered
inhibitory effect of OPN on apoptosis was confirmed on
cultured renal epithelial cells. The effects of OPN might
be mediated by the CD44 receptor since OPN is one
of the major ligands of this receptor which is found on
macrophages and lymphocytes and is, as OPN, involved in
cell migration [30]. Indeed CD44 knockout mice (CD−/−)
responded in a similar way to UUO: reduced cellular
infiltration (around 25% reduction), increased apopto-
sis, and decreased tubulointerstitial fibrosis compared to
wild-type mice [31].
Another group of adhesion molecules, selectins, were
studied for their involvement in cellular infiltration dur-
ing the development of obstructive nephropathy in 2-day-
old mice [32]. Three types of selectins exist: E-selectin
which is expressed on endothelial cells, P-selectin is ex-
pressed on endothelial cells and platelets, and L-selectins
is expressed on leukocytes. Triple selectin (EPL−/−)
and L-selectin (L−/−) knockout mice displayed signifi-
cantly less (56% and 32%, respectively) macrophage in-
filtration in the obstructed kidney than wild-type mice.
However, in contrast to OPN knockouts, the degree of
macrophage infiltration was correlated to the degree of
apoptotic tubular cells in these selectin knockout mice.
Both macrophage infiltration and apoptotic tubular cells
were lower in EPL−/− and L−/− mice than in wild-type
mice resulting at day 14 post-UUO in reduced tubular
atrophy and interstitial fibrosis. Another study showed
the importance of L-selectin in macrophage recruitment
but this time knockout mice for sulfatide were used, a
sulfated glycolipid that is an important L-selectin lig-
and [33]. The expression of sulfatide is modified during
obstructive nephropathy. In the normal kidney, sulfatide
is expressed in distal tubules; however, no leukocyte traf-
fic in this area is observed, but during UUO, sulfatide
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relocates to the interstitium and peritubular capillaries,
where monocytes are considered to extravasate into the
interstitium. The use of sulfatide knockout mice con-
firmed the interaction between sulfatide and L-selectin
and the role of this interaction in ureteral obstruction in-
duced macrophage infiltration [34]. Sulfatide deficiency
reduced by 50% macrophage infiltration but unfortu-
nately the effect on tubulointerstitial fibrosis was not
studied. Blockade of the interaction between sulfatide
and L-selectin could thus be a potential useful strategy to
block cellular infiltration in obstructive nephropathy.
Chemokine receptors
CCR1 and CCR5 are chemokine receptors [35] which
are induced by ureteral obstruction [24]. CCR1 and
CCR5 knockout mice have helped to establish that the
CCR1 receptor is responsible for leukocyte recruitment
after UUO and not the CCR5 receptor [36]. UUO in
CCR1 knockout mice resulted in reduced leukocyte re-
cruitment, reduced EMT, and significantly lower tubu-
lointerstitial fibrosis than their control littermates. The
use of an antagonist confirmed the effect of the CCR1
knockout. An interesting application of knockout mice
involved the transfer of cells between knockout and wild-
type strains to show the involvement of CCR receptors in
macrophage and T-cell recruitment in the inflammatory
phase of experimental hydronephrosis. Purified F4/80
macrophages and CD8 T cells of wild-type, CCR1−/−
and CCR5−/− mice were prepared and injected in the
circulation of obstructed wild-type mice. Three hours af-
ter injection, in vivo renal cell recruitment was reduced
for CCR1-deficient cells compared to CCR5-deficient or
wild-type cells confirming the importance of this CCR1
cellular recruitment. A similar cell transfer between wild-
type and knockout animals also revealed an interesting
feature of the AT1 receptor in UUO (see below).
Other than confirming the role of a number of
molecules involved in cellular infiltration in UUO and
attributing an antiapoptotic function to the adhesion
molecule OPN, the knockout animals showed that knock-
out of various molecules reduced but never completely
eliminated cellular infiltration showing that different,
independent pathways, are additive in leukocyte re-
cruitment during UUO. Other macrophage recruiting
molecules, including monocyte chemoattractant protein-
1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1),
and vascular cell adhesion molecule-1 (VCAM-1) have
been shown to be induced during ureteral obstruction
[37, 38].
PROLIFERATION/APOPTOSIS
Tubulointerstitial disease is associated with cell pro-
liferation and apoptosis; however, over time an imbal-
ance between these two processes leads to unchecked
apoptosis resulting in progressive cell loss and tubular
atrophy [39]. Cyclins and their catalytic partners cyclin-
dependent kinases (CDK) positively control cell prolif-
eration. Negative regulators of the cell cycle include the
cyclin-dependent kinase inhibitors (CKI). CKIs inhibit
the cell cycle at multiple checkpoints through inactiva-
tion of cyclin-CDK complexes [40]. Two families of CKIs
exist: the INK4 family and the CIP/KIP family. The lat-
ter includes p21WAF/CIP, p27KIP1, and p57KIP2 and inhibits
cyclin-CDK complexes during both G1 and S phases of
the cell cycle. p21WAF/CIP and p27KIP1 knockout mice are
available and were used to explore the role of these CKIs
in cell proliferation and apoptosis in experimental ob-
structive nephropathy [41, 42]. As expected for a CKI
knockout, UUO-induced tubular cell proliferation was
significantly higher in p27KIP1 knockout mice at day 3
than in the wild-type animals [41]. Surprisingly, UUO-
induced tubular cell proliferation was not modified in the
other CKI knockout, p21WAF/CIP, but in these mice inter-
stitial myofibroblast proliferation was temporarily higher
compared to wild-type mice [42]. However, no effect of
both CKIs knockout on UUO-induced tubulointerstitial
fibrosis was observed. These minor effects of both CKI
might be explained by cell or renal compartment specific
CKI effects (e.g., epithelial vs myofibroblasts or differen-
tial effects of UUO on renal compartments as was shown
by a recent UUO study on neonatal mice [43]) and func-
tional redundancy (gene-knockout compensation) as dis-
cussed above.
Before the use of genetically engineered animals, apop-
tosis was considered to be a crucial lesion in UUO [39,
44, 45]. The transcription factor p53, a well-known tu-
mor suppressor gene, is induced in UUO [46]. Activated
p53 can induce either cell cycle arrest or apoptosis. Af-
ter DNA damage, p53 blocks the progression of the cell
cycle until the DNA can be repaired, or, if damage is
extensive the cells enter into p53-induced apoptosis [47].
p53 knockout mice were used to determine the role of this
gene and apoptosis in the development of tubulointersti-
tial fibrosis in obstructive nephropathy [48]. p53 knock-
out mice (homo- and heterozygote) displayed between
50% and 70% less tubular and interstitial cell apopto-
sis which was accompanied by a reduced interstitial vol-
ume. As was observed with knockout mice for cellular
infiltration described above, the p53 knockout exhibited
attenuation not elimination of apoptosis, suggesting that
UUO-induced renal cell apoptosis proceeds through both
p53-dependent and -independent pathways. Interstitial
volume was lower in p53-deficient mice at day 7; how-
ever, no difference was observed at day 15 to 30, although
tubular and interstitial cell apoptosis were still different
at day 15. In contrast, tubular dilatation was correlated
with reduced apoptosis.
These above studies on the role of cell proliferation
and apoptosis using gene knockout animals were all but
conclusive about the role of these processes in the de-
velopment of tubulointerstitial fibrosis. The cell or renal
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Fig. 3. Proposed role of epithelial-mesenchymal transition (EMT) in ureteral obstruction. Unilateral ureteral obstruction (UUO) induces EMT
which contributes significantly (36%) to the appearance of interstitial myofibroblasts. Myofibroblasts are the main source of profibrotic and
inflammatory cytokines leading to matrix accumulation. The remainder of the fibroblasts comes from bone marrow (14% to 15%) and probably
local fibroblast proliferation and activation [98]. EMT involves four key events leading to epithelial cell migration and invasion into the interstitium
and transition into fibroblasts [49]. Interestingly one of these events, tubular basement membrane degradation, is blocked in tissue plasminogen
activator (tPA) knockout mice (in contrast to what was expected for a tPA knockout) thereby blocking EMT and subsequent tubulointerstitial
fibrosis. Abbreviations are MMP-9, matrix metalloproteinase-9; TGF-b , transforming growth factor-b ; a-SMA, a-smooth muscle actin.
compartment–specific and time-dependent effects and
the large number of mediators of cell proliferation and
apoptosis make the interpretation of these data obtained
with knockout mice difficult. More studies on different
knockouts or double knockouts combined with phar-
macologic tools, if possible, should give more insight
into these early and important events of obstructive
nephropathy.
FIBROBLAST ACCUMULATION
Irrespective of the initial cause, the development of
tubulointerstitial fibrosis is characterized by the appear-
ance of activated [a-smooth muscle actin (a-SMA)–
positive) fibroblasts (also called myofibroblasts). It is
widely accepted that these cells are the principal actors
responsible for ECM deposition [49]. The appearance
of myofibroblasts is also a prominent feature in the ob-
structed kidneys during ureteral obstruction [49]. While
the profibrotic role of myofibroblasts in renal fibrosis
is widely accepted, their origin(s) remains largely un-
clear. Three hypotheses have been proposed regarding
the origin of these cells during fibrogenesis (Fig. 3). One
hypothesis proposes that marrow stromal cells are the
progenitors for tissue fibroblasts that, via the circulation,
populate peripheral organs [50]. The second hypothesis
suggests that the myofibroblasts are derived from local
activation of resident interstitial fibroblasts [49]. Finally,
the third hypothesis proposes EMT for the generation
of local interstitial fibroblasts [51]. Tubular EMT is a
process in which renal tubular cells lose their epithe-
lial phenotype and acquire new features characteristic
of mesenchyme [49]. Using a combination of bone mar-
row chimeras, transgenic reporter mice and the fibroblast-
specific protein-1 (FSP-1) as a fibroblast marker, it was
shown that interstitial kidney fibroblasts arise from both
EMT (36%) and bone marrow (14% to 15%) while the
rest of the fibroblasts are most likely contributed by local
fibroblast proliferation during UUO. [52]. Thus EMT ap-
pears to be an important contributor to the appearance
of fibroblasts and consequently fibrogenesis in obstruc-
tive nephropathy and an interesting target in treatment
of tubulointerstitial fibrosis.
EMT involves four key events (Fig. 3): (1) loss of
epithelial adhesion properties, (2) de novo a-SMA ex-
pression and actin reorganization, (3) disruption of the
tubular basement membrane, and (4) enhanced cell mi-
gration and invasion capacity. TGF-b is currently the sole
factor described able to induce all four steps [53]. Two
molecules: hepatocyte growth factor (HGF) [54] in the
UUO-model and bone morphogenic protein-7 (BMP-7)
[55] in a model of tubulointerstitial fibrosis induced by
nephrotoxic serum have been shown to reverse (that is,
after establishment of renal fibrosis), via TGF-b inhibi-
tion, EMT, and subsequent renal fibrosis.
ECM ACCUMULATION
Tubulointerstitial fibrosis is the result of an imbalance
between ECM synthesis and degradation. The patho-
logic tubular ECM is composed of collagen I, III, and
IV, V, VII, XV, laminin and fibronectin [56]. ECM degra-
dation is thought to be largely dependent on the plas-
minogen system [plasminogen, plasminogen activators
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(UUO). The profibrotic role of angiotensin II (AII) in UUO (see Fig. 5) is counterbalanced by the production of bradykinin. It is proposed that
during UUO, bradykinin is activating the G protein–coupled B2 receptor which activates the proteolytic plasminogen activator (PA), combined
tissue and urokinase plasminogen activator activity) system [either directly or by inhibition of plasminogen activator inhibitor-1 (PAI-1)] which
in turn switches on matrix metalloproteinases (MMPs) promoting matrix degradation (bold dashed line). Angiotensin-converting enzyme (ACE)
inhibition thus blocks production of profibrotic Ang II and promotes accumulation of the antifibrotic peptide bradykinin. The role of the proteolytic
enzymes in matrix degradation in UUO is depicted in the gray area in figure. Both pro- and antifibrotic properties of this system have now been
proposed: (1) in UUO it was shown that plasmin can generate both profibrotic transforming growth factor-b (TGF-b) and antifibrotic hepatocyte
growth factor (HGF), (2) activation of MMPs degrades the extracellular matrix (ECM) but stimulates endothelial-mesencymal transition (EMT),
and (3) PAI-1 has been shown, besides its role to inhibit PA activity, to stimulate cellular infiltration in UUO.
(PAs), and plasmin] primarily via the activation of latent
matrix metalloproteinase (MMPs). The serine protease
plasmin is generated from its precursor plasminogen by
two different types of PAs: urokinase type (uPA) and
tissue type (tPA). Plasmin can directly degrade matrix
proteins fibronectin, laminin [57], proteoglycan [58], and
type IV collagen [59] and activates pro-MMP-1 [inter-
stitial collagenase [60]) and pro-MMP-3 (stromelysin-1)
[61]]. MMP-3 then activates MMP-9. Independently of
plasmin, uPA was shown to activate MMP-2 via mem-
brane type 1 (MT)-MMP [62]. In theory, the combined
activity of these enzymes is sufficient to degrade the ECM
but knockout mice for some of the components of the
ECM degrading enzyme pathways showed other, impor-
tant, roles for these proteins in the pathology of ureteral
obstruction (Fig. 4, gray area).
Deficiency in tPA, one of the two main plasmin-
forming enzymes should, in theory, aggravate obstruction
induced tubulointerstitial fibrosis; however, tPA-
deficient mice showed decreased ECM deposition in the
tubulointerstitium [21]. By a yet unknown mechanism,
deficiency of tPA was able to selectively block EMT
via reduced expression of MMP-9 in renal interstitial
fibroblasts thereby most probably reducing damage
of the tubular basement membrane (Fig. 3) and thus
inhibiting EMT. In addition, tPA deficiency did nor mod-
ify plasmin nor uPA activity in control and obstructed
kidneys, suggesting absence of an effect of the knockout
on the ECM degrading capability of these mice. The
absence of a decreased plasmin activity in these tPA
knockout mice might be explained by the fact that
plasminogen is present in high concentrations in plasma
(2 lmol/L) and that about 40% of this plasminogen
is present in extravascular sites [63]. Therefore the
plasminogen transforming activity of one PA (i.e., uPA
in the tPA knockouts) might be sufficient to maintain
wild-type plasmin levels. Thus, in contrast to what was
expected, the tPA knockouts unmasked a potential
aggravating role for tPA in EMT but did not provide
information about the role of this enzyme in plasmin
generation for ECM degradation in the pathogenesis of
tubulointerstitial fibrosis.
Another study seems to confirm the absence for a role
of plasmin in ECM degradation. This time it was not the
PAs that were studied but their main physiologic inhibitor
plasminogen activator protein-1 (PAI-1) [64]. PAI-1 is
up-regulated in almost all known renal diseases, includ-
ing UUO [65] showing a casual relationship between the
pathogenesis of renal disease and this molecule. Classi-
cally, it was thought that inhibition of the PA activity by
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PAI-1 reduced plasmin production and thus ECM degra-
dation. Indeed, UUO in PAI-1 knockout mice showed
that these mice had significantly lower tubulointerstitial
fibrosis than their control littermates [20]. But neither the
mean renal PAs nor plasmin activities were increased in
PAI-1−/− mice compared to PAI-1+/+ mice. Surprisingly,
it was the number of interstitial macrophages that was
dramatically lower in PAI-1 knockout mice which was
accompanied by less interstitial myofibroblasts and sig-
nificant reductions in mRNA levels for TGF-b and pro-
collagens I and III. This suggests that in this model PAI-1
is playing a proinflammatory rather than an antiprote-
olytic role.
The uPA receptor (uPAR) is a multifunctional pro-
tein that localizes pericellularly and binds components of
the urokinase plasmin activation system, including uPA
and PAI-1. Binding of PAI-1 to the uPA-uPAR complex
promotes internalization and degradation of both uPA
and PAI-1 [64]. The uPAR receptor might play a role
in the generation of active plasmin and thus in the renal
fibrogenic response. uPAR knockout mice were less resis-
tant to UUO-induced renal tubulointerstitial fibrosis than
wild-type mice which was accompanied by reduced renal
uPA, tPA and possibly MMP-9 activity [66]. Surprisingly
plasmin activity was not lower in uPAR knockouts, which
was attributed in this paper to improper assay conditions,
which seems likely especially since plasmin activity was
also not modified after obstruction in these experiments
in contrast to earlier experiments of this laboratory [20].
An interesting observation in these experiments is de-
creased HGF expression in after obstruction in uPAR−/−
mice compared to uPAR+/+ mice. uPA is known to ac-
tivate HGF [67]. The well-known antifibrotic activities
of HGF might also contribute, independently of an ef-
fect of the uPAR knockout on plasmin, to the observed
differences.
Another control point of the ECM-degrading machin-
ery is at the level of MMP activity inhibition. This is estab-
lished by tissue inhibitors of MMP (TIMPs). TIMPs, es-
pecially TIMP-1, are up-regulated during UUO-induced
hydronephrosis [68, 69]. However, knockout mice for
TIMP-1, the inhibitor of MMP-9, did not attenuate UUO-
induced tubulointerstitial fibrosis [70] although MMP-
9 activity was higher in kidneys of obstructed TIMP-1
knockout mice. Compensation by other TIMPs (TIMP-2
and -3) or PAI-1 or the possibility that inhibition of in-
trinsic MMP activity does not constitute a profibrogenic
event (i.e., MMP-9 inhibition resulting in less EMT as de-
scribed above) in the kidney might explain the absence
of an effect of the TIMP-1 knockout.
In conclusion, studying knockout mice for the “ECM
degrading enzyme system” has taught us more about less
conventional roles of these proteins (inflammation and
basal membrane degradation) than about their role in
interstitial ECM degradation.
RAS
A number of renal diseases and their progression to
ESRD involve Ang II making it an important target
in progressive renal disease. The different components
of the RAS are present in the kidney [71] and as de-
scribed above, Ang II and the RAS have been known
for a long time to be involved in the etiology of ob-
structive nephropathy [72, 73]. Ang II, formed from its
precursor angiotensinogen by the subsequent action of
renin and ACE (the major angiotensin I to II transform-
ing enzyme), activates two G protein–coupled receptors
the AT1 and AT2 receptor. Ang II signaling through the
AT1 receptor results in vasoconstriction, cell prolifera-
tion, and fibroblast activation while its counterpart, the
AT2 receptor, generally results in vasodilatation, inhibi-
tion of cell proliferation and increased apoptosis [74]. It
is generally accepted that stimulation of the AT1 receptor
is inducing the deleterious effects of the RAS. AT1 and
AT2 knockout and genetically engineered mice with zero
to four copies of the angiotensinogen gene exist. These
animals were explored to determine the role of the RAS
in experimental hydronephrosis and the results of these
studies have in general confirmed the important role of
the RAS in the pathology of obstructive nephropathy.
In mice with zero to four copies of the angiotensinogen
gene, UUO-induced renal interstitial collagen content in-
creased linearly with increasing angiotensin expression
(up to two copies and reaching a plateau above two copies
of the angiotensinogen gene [75]). This effect seems to
be mediated by the AT1 receptor since AT1a receptor
(the predominant form of the AT1 receptor in mice)
knockout mice develop significantly less UUO-induced
tubulointerstitial fibrosis [676]. In contrast, AT2 knock-
out display accelerated tubulointerstitial collagen depo-
sition after UUO [77]. The deleterious effects of Ang
II are thus most probably mediated by the AT1 recep-
tor. It appears that many of the effects of AT1 receptor
stimulation in tubulointerstitial fibrosis are mediated by
TGF-b1, TNF-a, and activation of NF-jB (Fig. 5) [78].
Angiotensinogen gene expression is stimulated by NF-jB
and since AT1 receptor stimulation induces NF-jB acti-
vation this provides a positive feedback loop to probably
maintain high Ang II levels under pathologic conditions
[79]. NF-jB is also strongly involved in TNF-a induction
during UUO [78] while TNF-a itself is a strong inducer
of NF-jB expression [80] providing an additional pos-
itive feedback loop in maintaining high NF-jB activity
during UUO. The interplay between Ang II and TNF-a
was studied in more detail using a combination of AT1a
and TNF receptor (TNFR1 and TNFR2) knockout mice
and pharmacologic tools [81]. It was shown that the dou-
ble TNF-a receptor knockout displayed around 40% less
tubulointerstitial fibrosis than the wild-type mice compa-
rable to what was observed observed for the AT1a knock-
out mice. This level of fibrosis in double TNF-a receptor
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Fig. 5. The central role for nuclear factor-jB (NF-jB) in angiotensin II profibrotic effects in unilateral ureteral obstruction (UUO). Angiotensin
II (AII) accumulation during UUO stimulates two G protein–coupled receptors, the angiotensin type 1 (AT1) and angiotensin type 2 (AT2).
Although AT2 knockout mice display less tubulointerstitial fibrosis, stimulation of this receptor and the AT1 receptor induces NF-jB activation
which translocates to the nucleus and activates a vast panel of proinflammatory and profibrotic cytokines leading to sustained inflammation and
matrix production. NF-jB activation is also leading to at least two positive autocrine regulation loops by the increased expression of tumor necrosis
factor-a (TNF-a) and angiotensinogen. IjB is inhibitor of jB.
knockout mice was further lowered with about 25% by
enalapril treatment (an ACE inhibitor) suggesting both
Ang II–dependent and –independent activation of the
TNF-a system. By studying TGF-b expression during
UUO, these analyses combining knockouts and pharma-
cology also showed that levels of this cytokine are almost
exclusively controlled by Ang II and do not involve TNF-
a–dependent pathways.
The above studies using classic knockout mice on the
RAS system confirmed the role for the AT1 receptor as an
important mediator of ECM accumulation during UUO.
However, an elegant study using bone marrow transplan-
tation from AT1 knockout mice to wild-type mice showed
that AT1 receptors can also participate in the reduction
of renal fibrosis in obstructive nephropathy [18]. When
the bone marrow of wild-type mice was replaced by bone
marrow of AT1 receptor knockout mice, these mice de-
veloped, in contrast to what was expected, more severe
interstitial fibrosis than non transplanted wild-type mice.
Mice transplanted with AT1 receptor knockout bone mar-
row had significantly lower numbers of peripheral blood
monocytes and macrophage progenitors in bone mar-
row with impaired phagocytic capabilities compared to
wild-type macrophages. It is suggested that the reduced
phagocytic capabilities of the AT1 receptor knockout
bone marrow–derived macrophages are at the origin of
this increased interstitial fibrosis by decreased phagocytic
clearance of ECM components and apoptotic cells in
these mice. This combined knockout and bone marrow
transplantation approach has thus allowed dissociation
between macrophage infiltration and renal fibrosis which
is not possible in “simple” knockouts and presents a draw-
back of classic nontemporal and nonspatial knockouts to
study complex pathologic processes.
ACE inhibition has shown long before the use of genet-
ically engineered animals to be very efficient in reducing
tubulointerstitial fibrosis in experimental hydronephro-
sis [15–17]. Besides blocking the conversion of Ang I into
Ang II, ACE inhibitors also act on the kinin-kallikrein
system by inhibiting the degradation of bradykinin [82],
which suggests a role for bradykinin in the reduction
of UUO-induced renal fibrosis and has opened research
into the role of bradykinin and related peptides in ob-
structive nephropathy (Fig. 4). Bradykinin acts on a G
protein–coupled receptor, the bradykinin B2 receptor.
Bradykinin B2 receptor knockout mice and transgenic
rats expressing increased endogenous bradykinin levels
[TGR (hKLK1) rats, overexpressing the bradykinin pro-
ducing enzyme kallikrein] were used to determine the
role of bradykinin and its B2 receptor in experimen-
tal hydronephrosis [83]. UUO-induced tubulointerstitial
fibrosis was twofold higher in bradykinin B2 receptor
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Fig. 6. Proposed schematic representation of the role of transforming growth factor-b (TGF-b) in unilateral ureteral obstruction (UUO). TGF-b has
been shown to be an important regulator of many of the processes leading to tubulointerstitial fibrosis, including epithelial-mesencymal transition
(EMT), cellular infiltration, and apoptosis leading to tubular atrophy and interstitial accumulation of extracellular matrix (ECM) proteins. Binding
of TGF-b to the transmembrane serine/threonine kinase receptor type II (RII) leads to the recruitment phosphorylation and activation of the type
I receptor kinase (RI), which, in turn, phosphorylates Smad2 and Smad 3 proteins thus able to bind Smad4 and translocate to the nucleus where
they regulate the transcription of target genes by binding to their specific promoter sequences. In addition to this classic TGF-b signaling pathway
there is now increasing evidence that Smad-independent pathways like activation of RhoA and p38 mitogen-activated protein kinases (MAPKs)
are involved in EMT. Smad3 knockout mice are protected against UUO-induced tubulointerstitial fibrosis and showed the existence of a TGF-b
autocrine loop during UUO. Furthermore, UUO on knockout mice showed that the production of active TGF-b is controlled by integrins, plasmin,
and decorin.
knockout mice compared to wild-type mice and signif-
icantly lower in transgenic TGR (hKLK1) than in wild-
type rats. This suggested that bradykinin via B2 receptor
activation was antifibrotic. No effects of the knockout
were observed on cell proliferation and fibroblast activa-
tion and on gene expression of a large number of genes
involved in the development of tubulointerstitial fibrosis.
However, the activity of proteolytic enzymes was sig-
nificantly lower (PAs, tPA and uPA, and MMP-2 activ-
ities) in the obstructed kidneys of B2 receptor knockout
compared to wild-type mice. This suggested that the cas-
cade bradykinin/B2 receptor/PA/MMP-2 was involved
in the lower level of tubulointerstitial fibrosis in wild-
type compared to B2 receptor knockout mice. Finally,
the bradykinin receptor knockout mice were used to de-
termine the role of bradykinin in the beneficial effects
of ACE inhibition on experimental hydronephrosis [84].
Surprisingly, although ACE inhibition lowered signifi-
cantly renal fibrosis, no difference was observed between
the degree of tubulointerstitial fibrosis in ACE inhibitor–
treated wild-type and B2 receptor knockout mice. In
contrast to the above study, it was recently shown in a
model of cyclosporine-induced interstitial fibrosis that
bradykinin was responsible for the antifibrotic effects of
ACE inhibitor benazepril which was accompanied by in-
creased plasmin activity [85, 86]. Further studies on lo-
cal renal bradykinin concentrations during UUO and
other interstitial fibrosis models, which might be modi-
fied since UUO has been shown to increase ACE activity
and decrease kallikrein expression [87], or effects on the
bradykinin B1 receptor are necessary to confirm the ab-
sence of a role for bradykinin in the protective effects of
ACE inhibitors in experimental hydronephrosis.
TGF-b–RELATED EFFECTS
As mentioned above, and long before the use of ge-
netically engineered animals, TGF-b was incriminated
as a key molecule in fibrosis (Fig. 6) [14]. Its expres-
sion is increased in numerous fibrotic conditions [88],
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including experimental and human hydronephrosis [89].
TGF-b1 (the main TGF-b isoform) knockout mice are
not viable and die at midgestation [90]. TGF-b synthe-
sis is strongly induced by Ang II and the profibrotic
actions of TGF-b are thought to involve reduction of
MMP expression, increased TIMP and PAI-1 expression,
and increased synthesis of matrix proteins. However, the
mechanism by which this occurs is not clear. UUO in
knockout mice of molecules interacting with TGF-b or
involved in TGF-b signaling helped in better understand-
ing of these mechanisms.
TGF-b activates transmembrane receptor ser-
ine/threonine kinases which transduce downstream
signals to cytoplasmic latent transcription factors called
Smads. Smad2 and 3 are directly phosphorylated by one
of these receptors after which they bind to Smad4 before
nuclear translocation where they act as transcriptional
regulators [91]. Unlike, TGF-b and Smad2, Smad3
knockout mice are viable although with a reduced life
span up to 6 months due to impaired mucosal immunity
[92] and has allowed to study the role of TGF-b signaling
in experimental hydronephrosis [93]. Smad3 knockout
mice are protected against UUO-induced tubuloin-
terstitial fibrosis which is accompanied by reduced
monocyte influx, EMT, and collagen deposition [93].
The results on Smad3 null mice and complementary
experiments in vitro show that it is probably the effect
of Smad3 on EMT that is the main profibrotic factor.
Furthermore, Smad3 is essential for TGF-b amplification
since TGF-b levels are extremely low after UUO in
Smad3 null mice compared to wild-type mice. Finally,
it was shown that the effect of Smad3 on monocyte
accumulation further stimulated EMT. This results in
a TGF-b/Smad3–induced profibrogenic myofibroblast
population which is probably responsible for the larger
part of UUO-induced tubulointerstitial fibrosis.
TGF-b is maintained in a latent form and can be ac-
tivated by binding to avb 6 integrin. Experimental hy-
dronephrosis in avb 6 integrin null mice resulted in signifi-
cantly lower tubulointerstitial fibrosis [94]. This decrease
in interstitial fibrosis was accompanied by lower TGF-
b , PAI-1, and collagen I and III mRNA levels suggest-
ing that interruption of TGF-b activation can protect
against tubulointerstitial fibrosis. However, the authors
of this study also explored a possible TGF-b indepen-
dent pathway to tubulointerstititial fibrosis by treating
the aVb 6 integrin knockout mice with Ang II, which in-
creased the collagen concentration to levels comparable
to obstructed wild-type mice. Interestingly, Ang II infu-
sion only mildly increased active TGF-b levels and did
not change Smad2 levels in aVb 6 integrin knockout mice
but significantly induced PAI-1 expression. These data
thus suggest TGF-b independent profibrotic effects of
Ang II with both pathways triggering PAI-1 expression
and resulting in increased interstitial fibrosis. The Ang
II–induced TGF-b independent pathway for PAI-1 in-
duction in UUO remains to be elucidated.
Other, small molecules interacting with TGF-b such
as decorin or endoglin can modify its action and knock-
out out mice for both molecules have shown a role for
decorin [95] but not for endoglin [96] in the development
of tubulointerstitial fibrosis.
CONCLUSION
Genetically modified animals have made a major con-
tribution to our current understanding of the pathogen-
esis of obstructive nephropathy. These animals, when
subjected to UUO, have yielded important information
about the beneficial and deleterious (or, controversially,
both “beneficial and deleterious”) role of a specific gene
product. Besides confirming the role of key-mediators
in obstructive nephropathy, such as TGF-b and Ang II
in macrophage infiltration, (myo)fibroblast accumulation
and ECM accumulation, the use of genetically engineered
animals has also modified our current vision of concepts
that were accepted to be true in obstructive nephropa-
thy (i.e., the beneficial and deleterious role of Ang II, the
deleterious role of MMP-9, role for PAI-1 in macrophage
recruitment).
The use of knockout mice has also shown the limi-
tations of genetically modified animals. Especially com-
pensation during development by closely related gene
products makes interpretation of the results with knock-
out mice difficult. This problem might be circumvented
by temporal knockouts (i.e., Cre-Lox systems) although
a pharmacologic knockdown is often easier to achieve.
Another problem of genetically modified animals is the
fact that these animals do not allow to study reversibility
of the pathology. This is an important issue since renal fi-
brosis is often already present in an advanced state when
renal disease is detected. Again temporal knockouts or
pharmacologic knockdown are good alternatives.
The use of genetically modified animals, mainly knock-
out of a single gene, has also underlined the complexity
and the interconnection of the different events that lead
to hydronephrosis. It shows that pharmacologic treat-
ment when aiming at one molecule at a time is prob-
ably not always the good strategy for treatment. These
studies have taught us that when blocking the RAS, one
decreases profibrotic TGF-b production but one prob-
ably also decreases macrophage clearance of apoptotic
cells and ECM fragments slowing down in the devel-
opment of hydronephrosis. Similarly, MMP-9 stimulates
on one hand EMT and on the other interstitial ECM
degradation. These studies thus showed that future phar-
macologic approaches to treat hydronephrosis should
consider both these deleterious and beneficial effects
of one molecule on the different stages of obstructive
nephropathy.
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